Barostim: Flipping the Parasympathetic Switch at ISHLT 2026

Heart failure management continues to present challenges despite advancements in guideline-directed medical therapy and device-based therapy options. At our ISHLT 2026 symposium, a multi-disciplinary faculty provided an overview of Barostim therapy in heart failure, reviewing its mechanism of action, clinical evidence, patient selection, surgical considerations, and real-world implementation. Faculty also shared strategies for building successful Barostim programs, discussed multi-disciplinary approaches to care, and provided an update on the BENEFIT-HF trial. Watch the presentations to learn more

Before You Flip the Switch: Understanding Barostim and Patient Selection

Peter Eckman, MD
Allina Health – Abbott Northwestern

Switching on Barostim: From Concept to Clinical Execution

Shelley Hall, MD
Baylor Scott & White

The Moment of Activation: Barostim Implant and Program Impact; a Cardiac Surgeons Perspective

Matthew Danter, MD
University of Kansas

The Next Flip: Emerging Trial BENEFIT-HF

Farooq Sheikh, MD
MedStar Health

Dr. Peter Eckman, Dr. Shelley Hall, Dr. Matthew Danter, and Dr. Farooq Sheikh are paid consultants for CVRx.